drugset

drugset / Trial / NCT00457795

24-hour IOP-lowering Effect of Brimonidine 0.1%

NCT00457795 ↗

Phase 4 Completed 15 enrolled Allergan

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension

Timeline

Start: 2006-12
Primary completion: 2009-02
Completion: 2009-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brimonidine	Small molecule	0.1 %	—

Indications